Baloxavir Treatment to Reduce Influenza Virus Transmission.

Details

• Alternative Title:
  The New England Journal of Medicine, 2025, v. 392, no. 16: Baloxavir Treatment to Reduce Influenza Virus Transmission.
• Journal Article:
  The New England Journal of Medicine
• Personal Author:
  Uyeki, Timothy M. ; Dugan, Vivien G. ; Daskalakis, Demetre C.
• Description:
  Antiviral treatment of influenza is recommended as soon as possible for hospitalized patients and for outpatients who are at increased risk for influenza-related complications. The Food and Drug Administration-approved oral antiviral agent oseltamivir is the most widely used antiviral medication for the treatment of influenza and for postexposure prophylaxis to control institutional outbreaks of influenza. Baloxavir marboxil (baloxavir) is an oral antiviral medication that is FDA-approved for early treatment (within 48 hours after symptom onset) of uncomplicated influenza and for postexposure prophylaxis against influenza in persons 5 years of age and older. Randomized, controlled trials of early treatment with baloxavir, as compared with oseltamivir or placebo, showed that the efficacy of a single dose of baloxavir was similar to that of oseltamivir taken twice daily for 5 days for reducing the time to alleviation of influenza symptoms in adolescents and adults, including those at increased risk for influenza-related complications. In addition, upper respiratory tract virus levels were significantly lower with baloxavir than with oseltamivir or placebo as early as 24 hours after treatment, a finding consistent with its mechanism of action in inhibiting viral replication.3,4 Early treatment with oseltamivir or baloxavir has efficacy in reducing the risks of some influenza-related complications, as compared with placebo.
• Content Notes:
  Author manuscript
• Subjects:
  • baloxavirbaloxavir: No Relevant Scope Data
  • Influenza, Human
  • Oseltamivir
  • Outpatients
  • United States Food and Drug Administration
  • Respiratory System
  • Virus Replication
  • Antiviral Agents
  • Disease Outbreaks
• Source:
  The New England Journal of Medicine, 2025, v. 392, no. 16
• DOI:
  https://doi.org/10.1056/NEJMe2503242
• ISSN:
  0028-4793 ; 1533-4406
• Pubmed ID:
  40267433
• Pubmed Central ID:
  PMC12362349
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Pages in Document:
  1652-1654 (4 pdf pages)
• Volume:
  392
• Issue:
  16
• Download URL:
  https://stacks.cdc.gov/view/cdc/261462/cdc_261462_DS1.pdf
• File Type:
  [PDF - 38.99 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:3a699fbed00af306281714d73fafb540bc3d57860c82335c483492ac647bcd43fb100e75bd2a90c777688bccd6207dff167aee015ba5912f3535231a924d1daa